Nephrocare Health Services Ltd
Nephrocare Health Services Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #13 of 33 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Nephrocare Health Services Ltd Q3 FY26 key numbers
- Revenue
- Overall revenue grew 1.8x from Rs. 437 crores in FY ‘23 to Rs. 733 crores in FY ‘25.
As stated in Nephrocare Health Services Ltd's Q3 FY26 earnings call transcript · published 7 Aug 2026. Reported figures, not investment advice.
The short version
Patient volumes grew at a CAGR of ~20% from FY ‘23 to FY ‘25 and continued to grow 15% YoY in 9-month FY ‘26. Revenue growth is expected at a CAGR of 15%-20% over the next 3-4 years.
From Nephrocare Health Services Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Patient volumes grew at a CAGR of ~20% from FY ‘23 to FY ‘25 and continued to grow 15% YoY in 9-month FY ‘26.
- Treatment volumes increased 17% YoY in 9-month FY ‘26, reflecting network expansion and higher utilization.
- Revenue per treatment (RPT) rose steadily, driven by penetration into higher-priced international markets; RPT grew 17% YoY in 9-month FY ‘26.
- Overall revenue grew 1.8x from Rs. 437 crores in FY ‘23 to Rs. 733 crores in FY ‘25.
- Guidance indicates 15%-20% revenue growth expected over the next 2-3 years.
- Incremental growth expected to come from a blend of domestic and international markets, with international revenue share increasing (already 41% in 9-month FY ’26, up from 12% in FY ‘23).
2 more points from Nephrocare Health Services Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Nephrocare Health Services Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Historically, NephroPlus invests around Rs. 100-125 crores annually in capital expenditure.
- The focus remains on ROCE (Return on Capital Employed) accretive projects for all capital allocation decisions.
- Expansion strategy involves doubling down on captive clinics and selectively pursuing PPP projects when economically viable.
- Open to acquisitions in existing geographies such as India and the Philippines to increase footprint.
- New geography entries (e.g., Saudi Arabia) involve initial investments in team building and infrastructure, with revenue expected to start ramping up a few quarters after commencement.
- Capital allocation is disciplined, prioritizing sustainable, long-term financial health over short-term gains.
2 more points from Nephrocare Health Services Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Nephrocare Health Services Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Nephrocare Health Services Ltd's call on order book
Create a free account to keep reading this call
Nephrocare Health Services Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹266 Cr, net profit ₹30 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Nephrocare Health Services Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre Ltd (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —
- Aster DM Quality Care Ltd (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthcare Ltd (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare Ltd (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Nephrocare Health Services Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Nephrocare Health Services Ltd Q3 FY26 results?
Patient volumes grew at a CAGR of ~20% from FY ‘23 to FY ‘25 and continued to grow 15% YoY in 9-month FY ‘26. Revenue growth is expected at a CAGR of 15%-20% over the next 3-4 years.
What is Nephrocare Health Services Ltd share price analysis?
Nephrocare Health Services Ltd currently shows a neutral. The stock trades at a P/E of 82.3 with a market cap of ₹7,006 Cr. Investors should review the full earnings analysis for detailed insights.
Is Nephrocare Health Services Ltd planning capital expenditure?
Historically, NephroPlus invests around Rs.
Keep Nephrocare Health Services Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.